Research updates, FDA changes, and industry developments. No fluff, just facts.
Irish team develops dissolving films that could replace weekly injections for tirzepatide and semaglutide users. Early results show promise for needle-phobic patients.
Major new study pools data from 16 placebo-controlled trials. The results are eye-opening for anyone choosing between tirzepatide and semaglutide.
Bayesian network meta-analysis shows tirzepatide 10mg and 15mg deliver superior weight reduction compared to other GLP-1s.
The triple agonist peptide shows promise in Phase 2 trials, but questions remain about safety, availability, and real-world effectiveness.
FDA enforcement against 503B compounding pharmacies has shifted the landscape for peptide access. Here's what happened and what it means.
Animal studies show real promise, but human evidence remains limited. Here's what we actually know about healing peptides.
Reconstitution errors are the #1 peptide mistake. Here's how to calculate doses correctly and avoid dangerous errors.
Research shows real wound healing and tissue repair effects beyond cosmetic marketing claims. Here's what GHK-Cu actually does.
Real-world injury recovery protocols from the peptide community. What works, what doesn't, and what you should know.
Recent bioavailability studies challenge oral BPC-157 effectiveness. Here's what the data shows about injection vs oral administration.
New enforcement actions and regulatory changes are reshaping GLP-1 peptide access. Here's what happened and what it means.
Quality testing reveals massive variations in peptide purity and potency. Here's how to read COAs and spot fake testing documents.